From the latest Q:
If this "Trade Debt Financing " is hard to get and has not been realized, why would $25M be "more than enough to launch the TBG products" when $64M was initially stated by Mr. Berman?
Quote:Financing Requirements
At June 30, 2019, we had cash of $88,191 and negative working capital of $1,174,434. We anticipate that we will require $64
million in trade debt financing to finance our expected sales of GenUltimate!, GenUltimate! Premier (for big box) GenUltimate! TBG,
and GenChoice!, as the current litigation ends in the company’s favor. Trade debt financing is traditional debt where the borrower
borrows cash from a finance company or a bank or other financial institution and at the term of the loan pays the lender back in cash.
The company has noted substantial disinformation in public forums regarding trade debt financing. The above paragraph is the
company’s final position regarding its trade debt posture. We will borrow money, finance manufacturing of our product purchases, and
then pay the money back to the lender. The lender may be a bank, finance company or insurance company. Fancy derivative and/or
OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v2.0 February 2019) Page 61 of 68
toxic equity financing will not be used. We will operate our operations like a business. This financing is hard to get for a small company,
nonetheless we will aspire to endure. Without the financing our sales will be curtailed.
Quote:This financing is hard to get for a small company,
nonetheless we will aspire to endure. Without the financing our sales will be curtailed.
If this "Trade Debt Financing " is hard to get and has not been realized, why would $25M be "more than enough to launch the TBG products" when $64M was initially stated by Mr. Berman?
2
